View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsNuvalent 配当と自社株買い配当金 基準チェック /06Nuvalent配当金を支払った記録がありません。主要情報n/a配当利回り-5.3%バイバック利回り総株主利回り-5.3%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jul 17Nuvalent, Inc. Announces Board and Committee ChangesAs previously disclosed in the Current Report on Form 8-K filed on June 9, 2026 with the U.S. Securities and Exchange Commission (the “SEC”) by Nuvalent, Inc., a Delaware corporation (the “Company”), on June 9, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), with GlaxoSmithKline LLC, a Delaware limited liability company (“Parent”), Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”) and, solely for purposes of Section 9.14 thereof, GSK plc, a public limited company organized under the laws of England and Wales (“Ultimate Parent”). In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (James R. Porter, Ph.D.; Grant C. Bogle; Michael L. Meyers, M.D., Ph.D.; Christy Oliger; Anna Protopapas; Ron Squarer; Sapna Srivastava, Ph.D.; and Cameron A. Wheeler, Ph.D.) resigned from his or her respective position as a member of the Company’s board of directors, and any committee thereof. As of the Effective Time, in accordance with the Merger Agreement, Justin T. Huang and Kevin T. Ryan, the directors of Purchaser immediately prior to the Effective Time, became the directors of the Company as the surviving corporation. As of the Effective Time, in accordance with the Merger Agreement, the officers of Purchaser immediately prior to the Effective Time became the officers of the Company as the surviving corporation. The officers of the Company as the surviving corporation as of the Effective Time are as follows: Justin T. Huang as President and Secretary, Kevin T. Ryan as Vice President and Treasurer, and Hatixhe Hoxha as Assistant Secretary. Biographical and other information with respect to Justin T. Huang, Kevin T. Ryan and Hatixhe Hoxha is set forth in Schedule I to the Offer to Purchase, a copy of which is attached as Exhibit (a)(1)(A) to the Tender Offer Statement on Schedule TO filed with the SEC by Parent on June 24, 2026 and is incorporated herein by reference.お知らせ • Jul 16Nuvalent, Inc.(NasdaqGS:NUVL) dropped from NASDAQ Biotechnology IndexNuvalent, Inc. has been dropped from the NASDAQ Biotechnology Index.お知らせ • Jun 10GlaxoSmithKline LLC entered into an Agreement and Plan of Merger to acquire Nuvalent, Inc. (NasdaqGS:NUVL) for $10 billion.GlaxoSmithKline LLC entered into an Agreement and Plan of Merger to acquire Nuvalent, Inc. (NasdaqGS:NUVL) for $10 billion on June 9, 2026. Under the terms of the merger agreement, GSK will commence a tender offer to acquire all of Nuvalent's outstanding shares of Class A and Class B common stock at a purchase price of $124 per share in cash within 10 business days. The aggregate equity value of the transaction is estimated to be $10.6 billion (£8.0 billion). Net of cash acquired. Following the closing of the tender offer, GSK expects to acquire any remaining shares of Nuvalent through a second-step merger under Delaware law at the same price per share. The transaction will be funded primarily from new and existing debt facilities plus cash, with no impact expected to GSK's credit rating. The Merger Agreement also provides that Nuvalent must pay GlaxoSmithKline a termination fee of $350.5 million if (i) the Board determines to terminate the Merger Agreement in order to enter into a definitive agreement with respect to a superior proposal and Nuvalent so terminates or (ii) in the event that the Merger Agreement is terminated by GlaxoSmithKline following a change of recommendation by the Board. The transaction is subject to customary closing conditions, including the tender of a majority of Nuvalent's outstanding shares of Class A common stock in the tender offer, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Act and approval of acquirer shareholders. The transaction is unanimously approved by both boards, and is expected to close in Q3, 2026. The acquisition is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029 inclusive of synergies and reprioritization. Leerink Partners LLC acted as financial advisor for GSK plc. Citigroup Inc. acted as financial advisor for GSK plc. The team of Davis Polk & Wardwell LLP led by William J. Chudd, Daniel Brass, Saagar Kaul. Partner Jennifer S. Conway, David R. Bauer, Howard Shelanski, Suzanne Munck af Rosenschold and William A. Curran acted as legal advisor for GSK plc. Slaughter and May acted as legal advisor for GSK plc. Centerview Partners LLC acted as financial advisor and fairness opinion provider for Nuvalent, Inc. Emily J. Oldshue, Nicholas C.H. Roper, Renata J. Ferrari, Christa Sanchez, Megan R. Baca, Jimmy Chen, Ruchit Patel, Michael S. McFalls, Benjamin Rogers, Joshua Oyster and Leslie A. Thornton of Roper Ropes & Gray LLP acted as legal advisor for Nuvalent, Inc. Jefferies LLC acted as financial advisor for Nuvalent, Inc. Sidley Austin LLP acted as legal advisor for Nuvalent, Inc.決済の安定と成長配当データの取得安定した配当: 5AXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 5AXの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Nuvalent 配当利回り対市場5AX 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (5AX)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.7%業界平均 (Biotechs)2.2%アナリスト予想 (5AX) (最長3年)0%注目すべき配当: 5AXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 5AXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 5AXの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: 5AXが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/17 12:33終値2026/07/15 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nuvalent, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24 アナリスト機関Colleen KusyBairdEtzer DaroutBarclaysJeffrey WalchBernstein21 その他のアナリストを表示
お知らせ • Jul 17Nuvalent, Inc. Announces Board and Committee ChangesAs previously disclosed in the Current Report on Form 8-K filed on June 9, 2026 with the U.S. Securities and Exchange Commission (the “SEC”) by Nuvalent, Inc., a Delaware corporation (the “Company”), on June 9, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), with GlaxoSmithKline LLC, a Delaware limited liability company (“Parent”), Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”) and, solely for purposes of Section 9.14 thereof, GSK plc, a public limited company organized under the laws of England and Wales (“Ultimate Parent”). In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (James R. Porter, Ph.D.; Grant C. Bogle; Michael L. Meyers, M.D., Ph.D.; Christy Oliger; Anna Protopapas; Ron Squarer; Sapna Srivastava, Ph.D.; and Cameron A. Wheeler, Ph.D.) resigned from his or her respective position as a member of the Company’s board of directors, and any committee thereof. As of the Effective Time, in accordance with the Merger Agreement, Justin T. Huang and Kevin T. Ryan, the directors of Purchaser immediately prior to the Effective Time, became the directors of the Company as the surviving corporation. As of the Effective Time, in accordance with the Merger Agreement, the officers of Purchaser immediately prior to the Effective Time became the officers of the Company as the surviving corporation. The officers of the Company as the surviving corporation as of the Effective Time are as follows: Justin T. Huang as President and Secretary, Kevin T. Ryan as Vice President and Treasurer, and Hatixhe Hoxha as Assistant Secretary. Biographical and other information with respect to Justin T. Huang, Kevin T. Ryan and Hatixhe Hoxha is set forth in Schedule I to the Offer to Purchase, a copy of which is attached as Exhibit (a)(1)(A) to the Tender Offer Statement on Schedule TO filed with the SEC by Parent on June 24, 2026 and is incorporated herein by reference.
お知らせ • Jul 16Nuvalent, Inc.(NasdaqGS:NUVL) dropped from NASDAQ Biotechnology IndexNuvalent, Inc. has been dropped from the NASDAQ Biotechnology Index.
お知らせ • Jun 10GlaxoSmithKline LLC entered into an Agreement and Plan of Merger to acquire Nuvalent, Inc. (NasdaqGS:NUVL) for $10 billion.GlaxoSmithKline LLC entered into an Agreement and Plan of Merger to acquire Nuvalent, Inc. (NasdaqGS:NUVL) for $10 billion on June 9, 2026. Under the terms of the merger agreement, GSK will commence a tender offer to acquire all of Nuvalent's outstanding shares of Class A and Class B common stock at a purchase price of $124 per share in cash within 10 business days. The aggregate equity value of the transaction is estimated to be $10.6 billion (£8.0 billion). Net of cash acquired. Following the closing of the tender offer, GSK expects to acquire any remaining shares of Nuvalent through a second-step merger under Delaware law at the same price per share. The transaction will be funded primarily from new and existing debt facilities plus cash, with no impact expected to GSK's credit rating. The Merger Agreement also provides that Nuvalent must pay GlaxoSmithKline a termination fee of $350.5 million if (i) the Board determines to terminate the Merger Agreement in order to enter into a definitive agreement with respect to a superior proposal and Nuvalent so terminates or (ii) in the event that the Merger Agreement is terminated by GlaxoSmithKline following a change of recommendation by the Board. The transaction is subject to customary closing conditions, including the tender of a majority of Nuvalent's outstanding shares of Class A common stock in the tender offer, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Act and approval of acquirer shareholders. The transaction is unanimously approved by both boards, and is expected to close in Q3, 2026. The acquisition is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029 inclusive of synergies and reprioritization. Leerink Partners LLC acted as financial advisor for GSK plc. Citigroup Inc. acted as financial advisor for GSK plc. The team of Davis Polk & Wardwell LLP led by William J. Chudd, Daniel Brass, Saagar Kaul. Partner Jennifer S. Conway, David R. Bauer, Howard Shelanski, Suzanne Munck af Rosenschold and William A. Curran acted as legal advisor for GSK plc. Slaughter and May acted as legal advisor for GSK plc. Centerview Partners LLC acted as financial advisor and fairness opinion provider for Nuvalent, Inc. Emily J. Oldshue, Nicholas C.H. Roper, Renata J. Ferrari, Christa Sanchez, Megan R. Baca, Jimmy Chen, Ruchit Patel, Michael S. McFalls, Benjamin Rogers, Joshua Oyster and Leslie A. Thornton of Roper Ropes & Gray LLP acted as legal advisor for Nuvalent, Inc. Jefferies LLC acted as financial advisor for Nuvalent, Inc. Sidley Austin LLP acted as legal advisor for Nuvalent, Inc.